PTrana Meditama Metropolitan Tbk (ISX:SAME) Notes Receivable: Rp0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:SAME PT Sarana Meditama Metropolitan Tbk ISX:SAME
79 GF Score
Price Rp306.00
GF Value Rp355.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PTrana Meditama Metropolitan Tbk Notes Receivable?

PTrana Meditama Metropolitan Tbk ISX:SAME -0.65% 79 Notes Receivable is Rp0 Mil as of Mar. 2026. GuruFocus rates ISX:SAME with a GF Score™ of 79/100 and a GF Value™ of Rp355.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

PTrana Meditama Metropolitan Tbk's Notes Receivable for the quarter that ended in Mar. 2026 was Rp0 Mil.

PTrana Meditama Metropolitan Tbk Notes Receivable Related Terms

PTrana Meditama Metropolitan Tbk Notes Receivable Historical Data

* Premium members only.

The historical data trend for PTrana Meditama Metropolitan Tbk's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTrana Meditama Metropolitan Tbk Notes Receivable Chart

PTrana Meditama Metropolitan Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PTrana Meditama Metropolitan Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ISX:SAME
79GF Score
PT Sarana Meditama Metropolitan Tbk ISX:SAME
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTrana Meditama Metropolitan Tbk Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of Rp0 Mil mean?
PTrana Meditama Metropolitan Tbk (ISX:SAME) has a Notes Receivable of Rp0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PTrana Meditama Metropolitan Tbk and its competitors.
Is PTrana Meditama Metropolitan Tbk's Notes Receivable too high?
PTrana Meditama Metropolitan Tbk's current Notes Receivable is Rp0 Mil. Overall, PTrana Meditama Metropolitan Tbk has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PTrana Meditama Metropolitan Tbk's Notes Receivable compare to HCA and THC?
PTrana Meditama Metropolitan Tbk's Notes Receivable of Rp0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PTrana Meditama Metropolitan Tbk and its competitors. PTrana Meditama Metropolitan Tbk's current Notes Receivable is Rp0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTrana Meditama Metropolitan Tbk stock overvalued right now?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk (ISX:SAME) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp355.17, compared to a current price of Rp306.00 — trading 13.8% below its estimated fair value. The current Notes Receivable is Rp0 Mil. PTrana Meditama Metropolitan Tbk's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For PTrana Meditama Metropolitan Tbk (ISX:SAME), the current Notes Receivable is Rp0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTrana Meditama Metropolitan Tbk (ISX:SAME) Overvalued in 2026?

Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk stock appears to be undervalued. The current stock price of Rp306.00 is trading 13.8% below its estimated GF Value™ of Rp355.17. GuruFocus considers PTrana Meditama Metropolitan Tbk to be Modestly Undervalued.

Key valuation signals for ISX:SAME:

  • Notes Receivable: Rp0 Mil
  • GF Value™: Rp355.17 vs. price of Rp306.00 (13.8% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the ISX:SAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTrana Meditama Metropolitan Tbk Business Description

Address Jalan Pulomas Barat VI No. 20, RS EMC Pulomas, Kayu Putih, Pulogadung, Jakarta Timur, Jakarta, IDN, 13210
PT Sarana Meditama Metropolitan Tbk is engaged in managing hospitals. Its hospitals are operated under the brand name Omni Hospital. The company manages and evaluates its business based on its geographic location consisting of Omni Pulomas, Omni Alam Sutera, Omni Cikarang, OMNI Pekayon, and others. It operates in Banten, DKI Jakarta, and West Java.
79GF Score

Get the complete analysis for ISX:SAME

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp306.00
Price
Rp355.17
GF Value